Amgen (AMGN) Competitors

Amgen has a net margin of 20.96% compared to Moderna's net margin of -143.55%. Amgen's return on equity of 137.41% beat Moderna's return on equity.

In the previous week, Amgen had 23 more articles in the media than Moderna. MarketBeat recorded 76 mentions for Amgen and 53 mentions for Moderna. Amgen's average media sentiment score of 0.91 beat Moderna's score of 0.04 indicating that Amgen is being referred to more favorably in the media.

Amgen currently has a consensus target price of $357.12, suggesting a potential upside of 8.35%. Moderna has a consensus target price of $35.73, suggesting a potential downside of 23.50%. Given Amgen's stronger consensus rating and higher possible upside, analysts clearly believe Amgen is more favorable than Moderna.

Amgen has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Amgen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

76.5% of Amgen shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 10.8% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a net margin of 32.94% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Vertex Pharmaceuticals' return on equity.

In the previous week, Amgen had 36 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 76 mentions for Amgen and 40 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.00 beat Amgen's score of 0.91 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Amgen currently has a consensus target price of $357.12, suggesting a potential upside of 8.35%. Vertex Pharmaceuticals has a consensus target price of $554.83, suggesting a potential upside of 30.74%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Amgen.

Amgen has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Amgen has higher revenue and earnings than Vertex Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

76.5% of Amgen shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.9% of Amgen shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AbbVie currently has a consensus target price of $252.90, suggesting a potential upside of 22.70%. Amgen has a consensus target price of $357.12, suggesting a potential upside of 8.35%. Given AbbVie's stronger consensus rating and higher probable upside, equities analysts plainly believe AbbVie is more favorable than Amgen.

Amgen has lower revenue, but higher earnings than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Amgen has a net margin of 20.96% compared to AbbVie's net margin of 5.79%. Amgen's return on equity of 137.41% beat AbbVie's return on equity.

70.2% of AbbVie shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, AbbVie had 24 more articles in the media than Amgen. MarketBeat recorded 100 mentions for AbbVie and 76 mentions for Amgen. Amgen's average media sentiment score of 0.91 beat AbbVie's score of 0.87 indicating that Amgen is being referred to more favorably in the news media.

AbbVie has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.44, suggesting that its stock price is 56% less volatile than the S&P 500.

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 3.4%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. AbbVie pays out 340.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen pays out 70.1% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Amgen has raised its dividend for 14 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has a net margin of 20.96% compared to Astrazeneca's net margin of 17.19%. Amgen's return on equity of 137.41% beat Astrazeneca's return on equity.

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.4%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.1%. Astrazeneca pays out 73.4% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Amgen had 25 more articles in the media than Astrazeneca. MarketBeat recorded 76 mentions for Amgen and 51 mentions for Astrazeneca. Amgen's average media sentiment score of 0.91 beat Astrazeneca's score of 0.66 indicating that Amgen is being referred to more favorably in the news media.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 76.5% of Amgen shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Astrazeneca has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Astrazeneca has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500.

Astrazeneca presently has a consensus target price of $205.33, suggesting a potential upside of 13.22%. Amgen has a consensus target price of $357.12, suggesting a potential upside of 8.35%. Given Astrazeneca's stronger consensus rating and higher probable upside, analysts plainly believe Astrazeneca is more favorable than Amgen.